3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia

International Journal of Neuropsychopharmacology

Volumn 14, Issue 6, 2011, Pages 756-767

  Condray, Ruth ^a,b   Dougherty, George G ^a,b   Keshavan, Matcheri S ^b,c   Reddy, Ravinder D ^a,b   Haas, Gretchen L ^a,b   Montrose, Debra M ^b   Matson, Wayne R ^a   McEvoy, Joseph ^d,e   Kaddurah Daouk, Rima ^e   Yao, Jeffrey K ^a,b,f  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d John Umstead Hospital   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

3 hydroxykynurenine; Cognition; first episode psychosis; neuroleptic naive; neurological symptoms; schizophrenia; tryptophan

Indexed keywords

3 HYDROXYKYNURENINE; TRYPTOPHAN;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COULOMETRY; DISEASE SEVERITY; ELECTROCHEMISTRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MENTAL PATIENT; NARCOLEPSY; PRIORITY JOURNAL; SCHIZOPHRENIA; TRYPTOPHAN METABOLISM;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BRIEF PSYCHIATRIC RATING SCALE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HUMANS; KYNURENINE; MONTE CARLO METHOD; NEUROPSYCHOLOGICAL TESTS; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; TRYPTOPHAN; YOUNG ADULT;

EID: 79958813560     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145710001689     Document Type: Article

References (66)

1. Alkondon M, Pereira EFR, Yu P, Arruda EZ, et al. (2004). Targeted deletion of the kynurenine aminotransferase II gene reveals a critical role of endogenous kynurenic acid in the regulation of synaptic transmission via a7 nicotinic receptors in the hippocampus. Journal of Neuroscience 24, 4635-4648. (Pubitemid 38656619)
2. Andreasen NC (1983). Scale for the Assessment of Negative Symptoms (SANS). Iowa City, IA: University of Iowa.
3. Andreasen NC (1984). Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, IA: University of Iowa.
4. Aschcroft GW, Crawford TBB, Eccleston D, Sharman DF, et al. (1966). 5-Hydroxyindole compounds in the cerebrospinal fluid of patients with psychiatric or neurological disease. Lancet 2, 1049-1052.
5. Barry S, Clarke G, Scully P, Dinan TG (2009). Kynurenine pathway in psychosis: evidence of increased tryptophan degradation. Journal of Psychopharmacology 23, 287-294.
6. Buchanan RW, Heinrichs DW (1989). The Neurological Evaluation Scale (NES): a structured instrument for the assessment of neurological signs in schizophrenia. Psychiatry Research 27, 335-350. (Pubitemid 19096791)
7. Carlsson A, Lindqvist M (1963). Effect of chlorpromazine or haloperidol on the formation of 3-methoxytyramine and mormetanephrine in mouse brain. Acta Pharmacologica et Toxicologica (Copenhagen) 20, 140-144.
8. Chess AC, Bucci DJ (2006). Increased concentration of cerebral kynurenic acid alters stimulus processing and conditioned responding. Behavioural Brain Research 170, 326-332. (Pubitemid 44255505)
9. Chess AC, Simoni MK, Alling TE, Bucci DJ (2007). Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophrenia Bulletin 33, 797-804. (Pubitemid 47343705)
10. Clish CB, Davidov E, Oresic M, Plasterer TN, et al. (2004). Integrative biological analysis of the APOE*3-leiden transgenic mouse. OMICS 8, 3-13. (Pubitemid 38481151)
11. Drton M, Perlman MD (2004). Model selection for Gaussian concentration graphs. Biometrika 91, 591-602. (Pubitemid 41309895)
12. Endicott J, Spitzer RL, Fleiss JL, Cohen J (1976). The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry 33, 766-771.
13. Erhardt S, Blennow K, Nordin C, Skogh E, et al. (2001). Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neuroscience Letters 313, 96-98. (Pubitemid 32973903)
14. Erhardt S, Schwieler L, Emanuelsson C, Geyer M (2004). Endogenous kynurenic acid disrupts prepulse inhibition. Biological Psychiatry 56, 255-260. (Pubitemid 39092940)
15. Foster AC, Collins JF, Schwarcz R (1983). On the excitotoxic properties of quinolinic acid, 2,3-piperidine dicarboxylic acids and structurally related compounds. Neuropharmacology 22, 1331-1342. (Pubitemid 14222225)
16. Garelis E, Gillin J, Wyatt R, Neff N (1975). Elevated blood serotonin concentration in unmedicated chronic schizophrenic patients. American Journal of Psychiatry 132, 184-186.
17. Geyer MA, Vollenweider FX (2008). Serotonin research: contributions to understanding psychoses. Trends in Pharmacological Science 29, 445-453.
18. Guidetti P, Schwarcz R (1999). 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum. European Journal of Neuroscience 11, 3857-3863. (Pubitemid 29537565)
19. Guy W (1976). Clinical global impressions. In: ECDEU Assessment Manual for Psychopharmacology (Revised) (pp. 217-221). Rockville: National Institute of Mental Health.
20. Häfner H, Maurer K, Trendler G, an der Heiden W, et al. (2005). Schizophrenia and depression: challenging the paradigm of two separate diseases - a controlled study of schizophrenia, depression and healthy controls. Schizophrenia Research 77, 11-24. (Pubitemid 40957057)
21. Henze N, Zirkler B (1990). A class of invariant consistent tests for multivariate normality. Communications in Statistics - Theory and Methods 19, 3595-3617.
22. Hilmas C, Pereira EFR, Alkondon M, Rassoulpour A, et al. (2001). The brain metabolite kynurenic acid inhibits a7 nicotinic receptor activity and increases non-a7 nicotinic receptor expression: physiopathological implications. Journal of Neuroscience 21, 7463-7473. (Pubitemid 32904945)
23. Hollingshead A (1975). Four Factor Index of Social Status. New Haven: Department of Sociology, Yale University.
24. Howes OD, Kapur S (2009). The dopamine hypothesis of schizophrenia: Version III - the final common pathway. Schizophrenia Bulletin 35, 549-562.
25. Issa F, Kirch DG, Gerhardt GA, Bartko JJ, et al. (1994). A multidimensional approach to analysis of cerebrospinal fluid biogenic amines in schizophrenia: II. Correlations with psychopathology. Psychiatry Research 52, 251-258. (Pubitemid 24225422)
26. Iyer SN, Boekestyn L, Cassidy CM, King S, et al. (2008). Signs and symptoms in the pre-psychotic phase: description and implications for diagnostic trajectories. Psychological Medicine 38, 1147-1156. (Pubitemid 351950151)
27. Javitt DC (2007). Glutamate and schizophrenia : phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. International Review of Neurobiology 78, 69-108.
28. Javitt DC, Laruelle M (2006). Neurochemical theories. In: Lieberman JA, Stroup TS, Perkins DO (Eds), Textbook of Schizophrenia (pp. 85-116). Washington, DC: American Psychiatric Publishing.
29. Johnson RA, Wichern DS (1998). Applied Multivariate Statistical Analysis (4th edn). Upper Saddle River: Prentice Hall.
30. Kaddurah-Daouk R, Krishnan KR (2009). Metabolomics: a global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacology 34, 173-186.
31. Kaddurah-Daouk R, Kristal BS, Weinshilboum RM (2008). Metabolomics: a global biochemical approach to drug response and disease. Annual Review of Pharmacology and Toxicology 48, 653-683. (Pubitemid 351738167)
32. Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, et al. (2007). Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Molecular Psychiatry 12, 934-945. (Pubitemid 47482696)
33. Keshavan MS, Sanders RD, Sweeney JA, Diwadkar VA, et al. (2003). Diagnostic specificity and neuroanatomical validity of neurological abnormalities in first-episode psychoses. American Journal of Psychiatry 160, 1298-1304. (Pubitemid 41070947)
34. Kristal BS, Shurubor YI, Kaddurah-Daouk R, Matson WR (2007). Metabolomics in the study of aging and caloric restriction. Methods in Molecular Biology 371, 393-409. (Pubitemid 350183437)
35. Larntz K, Perlman MD (1988). A simple test for the equality of correlation matrices. In: Gupta SS, Berger JO (Eds), Statistical Decision Theory and Related Topics IV, vol. 2 (pp. 289-298). New York: Springer.
36. Lieberman JA, Koreen AR (1993). Neurochemistry and neuroendocrinology of schizophrenia, a selective review. Schizophrenia Bulletin 19, 371-429. (Pubitemid 23183154)
37. Mannelli P, Patkar A, Rozen S, Matson W, et al. (2009). Opioid use affects antioxidant activity and purine metabolism: preliminary results. Human Psychopharmacology 24, 666-675.
38. Manowitz P, Gilmour DG, Racevskis J (1973). Low plasma tryptophan levels in recently hospitalized schizophrenics. Biological Psychiatry 6, 109-118.
39. Mittal VA, Hasenkamp W, Sanfilipo M, Wieland S, et al. (2007). Relation of neurological soft signs to psychiatric symptoms in schizophrenia. Schizophrenia Research 94, 37-44. (Pubitemid 47044872)
40. Muck-Seler D, Jakovlievie M, Deanovie Z (1988). Time course of schizophrenia and platelet 5-HT level. Biological Psychiatry 23, 243-251. (Pubitemid 18047593)
41. Olney JW, Newcomer JW, Farber NB (1999). NMDA receptor hypofunction model of schizophrenia. Journal of Psychiatric Research 33, 523-533.
42. Overall JE, Gorham DR (1962). The Brief Psychiatric Rating Scale. Psychological Reports 10, 799-812.
43. Owens DGC, Miller P, Lawrie SM, Johnstone EC (2005). Pathogenesis of schizophrenia: a psychopathological perspective. British Journal of Psychiatry 186, 386-393. (Pubitemid 40663420)
44. Patkar AA, Rozen S, Mannelli P, Matson W, et al. (2009). Alterations in tryptophan and purine metabolism in cocaine addiction: a metabolomic study. Psychopharmacology 206, 479-489.
45. Pedhazur EJ (1997). Multiple Regression in Behavioral Research (3rd edn). Belmont: Wadsworth.
46. Reddy R, Keshavan M, Yao JK (2007). Blunted serotonergic responsivity in neuroleptic-naive patients at first-episode of schizophrenia. Schizophrenia Research 90, 81-85. (Pubitemid 46177574)
47. Romm KL, Rossberg JI, Berg AO, Barrett EA, et al. (2010). Depression and depressive symptoms in first episode psychosis. Journal of Nervous and Mental Disease 198, 67-71.
48. Rozen S, Cudkowicz ME, Bogdanov M, Matson WR, et al. (2005). Metabolomic analysis and signatures in motor neuron disease. Metabolomics 1, 101-108. (Pubitemid 40778831)
49. Sanders RD, Keshavan MS, Forman SD, Pieri JN, et al. (2000). Factor structure of neurological examination abnormalities in unmedicated schizophrenia. Psychiatry Research 95, 237-243.
50. Sanders RD, Schuepbach D, Goldstein G, Haas GL, et al. (2004). Relationships between cognitive and neurological performance in neuroleptic-naive psychosis. Journal of Neuropsychiatry and Clinical Neurosciences 16, 480-487. (Pubitemid 39648350)
51. Scharfman HE, Goodman JH, Schwarcz R (2000). Electrophysiological effects of exogenous and endogenous kynurenic acid in the rat brain: studies in vivo and in vitro. Amino Acids 19, 283-297.
52. Schwarcz R, Rassoulpour A, Wu H-Q, Medoff D, et al. (2001). Increased cortical kynurenate content in schizophrenia. Biological Psychiatry 50, 521-530. (Pubitemid 32971883)
53. Schwieler L, Linderholm KR, Nilsson-Todd LK, Erhardt S, et al. (2008). Clozapine interacts with the glysine site of the NMDA receptor: electrophysiological studies of dopamine neurons in the rat ventral tegmental area. Life Sciences 83, 170-175.
54. Shepard PD, Joy B, Clerkin L, Schwarcz R (2003). Micromolar brain levels of kynurenic acid are associated with a disruption in auditory sensory gating in the rat. Neuropsychopharmacology 28, 1454-1462. (Pubitemid 41070880)
55. Shi H, Vigneau-Callahan KE, Matson WR, Kristal BS (2002). Attention to relative response across sequential electrodes improves quantitation of coulemetric array. Analytical Biochemistry 302, 239-245. (Pubitemid 34229729)
56. Stahl SM, Wood DJ, Mefford IN, Berger PA, et al. (1983). Hyperserotonemia and platelet serotonin uptake and release in schizophrenia and affective disorders. American Journal of Psychiatry 140, 26-30. (Pubitemid 13221714)
57. Stone TW (1993). Neuropharmacology of quinolinic and kynurenic acids. Pharmacological Reviews 45, 309-379. (Pubitemid 23292874)
58. Tamminga CA (1998). Schizophrenia and gluatmatergic transmission. Critical Review Neurobiology 12, 21-36.
59. Tandon R, Keshavan MS, Nasrallah HA (2008). Schizophrenia, 'Just the facts': what we know in 2008. Part 1: overview. Schizophrenia Research 100, 4-19.
60. Watanabe Y, Himi T, Saito H, Abe K (1992). Involvement of glycine site associated with NMDA receptor in hippocampal long-term potentiation and acquisition of spatial memory in rats. Brain Research 582, 58-64.
61. Wonodi I, Schwarcz R (2010). Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in schizophrenia. Schizophrenia Bulletin 36, 211-218.
62. Woods SW (2003). Chlorpromazine equivalent doses for the newer atypical antipsychotics. Journal of Clinical Psychiatry 64, 663-667. (Pubitemid 36750143)
63. Yao JK, Cheng P (2004). Determination of multiple redox-active compounds by high-performance liquid chromatography with coulometric multi-electrode array system. Journal of Chromatography B810, 93-100. (Pubitemid 39195028)
64. Yao JK, Dougherty Jr. GG, Reddy RD, Keshavan MS, et al. (2010a). Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Molecular Psychiatry 15, 938-953.
65. Yao JK, Dougherty Jr. GG, Reddy RD, Keshavan MS, et al. (2010b). Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naive patients with schizophrenia. PLoS One 5, e9508.
66. Yao JK, Reddy RD (2005). Metabolic investigation in psychiatric disorders. Molecular Neurobiology 31, 193-203. (Pubitemid 41271203)